Thalidomide in multiple myeloma: past, present and future.
about
Early experience with novel immunomodulators for cancer treatmentAnti-angiogenic therapy in glioma.Therapeutic non-toxic doses of TNF induce significant regression in TNFR2-p75 knockdown Lewis lung carcinoma tumor implants.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionInhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin.Asiatic acid, a triterpene, inhibits cell proliferation through regulating the expression of focal adhesion kinase in multiple myeloma cells.
P2860
Thalidomide in multiple myeloma: past, present and future.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Thalidomide in multiple myeloma: past, present and future.
@ast
Thalidomide in multiple myeloma: past, present and future.
@en
type
label
Thalidomide in multiple myeloma: past, present and future.
@ast
Thalidomide in multiple myeloma: past, present and future.
@en
prefLabel
Thalidomide in multiple myeloma: past, present and future.
@ast
Thalidomide in multiple myeloma: past, present and future.
@en
P2860
P356
P1433
P1476
Thalidomide in multiple myeloma: past, present and future.
@en
P2093
Jean-Luc Harousseau
P2860
P304
P356
10.2217/14796694.2.5.577
P407
P577
2006-10-01T00:00:00Z